No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RLAY240621C5000
- 1.55
- -0.65-29.55%
15min DelayClose Jun 20 15:58 ET
1.55High1.55Low
1.55Open2.20Pre Close5 Volume16 Open Interest5.00Strike Price775.00Turnover1676.66%IV-4.38%PremiumJun 21, 2024Expiry Date1.85Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.7907Delta0.0436Gamma2.12Leverage Ratio-1.0921Theta0.0001Rho1.68Eff Leverage0.0011Vega
Intraday
- 5D
- Daily
News
Relay Closes $35 Million Series B Funding to Drive Greater Productivity and Safety for Frontline Businesses and Workers
Led by G2 Venture Partners, funding will fuel Relay's rapid growth and innovation of new products to serve industries ranging from hospitality to healthcareRALEIGH, N.C., June 10, 2024 /PRNewswire/ -
Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 29% Of Holding
Anyone interested in Relay Therapeutics, Inc. (NASDAQ:RLAY) should probably be aware that the Chief Corporate Development Officer, Peter Rahmer, recently divested US$129k worth of shares in the compan
Stifel Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $28
Stifel analyst Bradley Canino maintains $Relay Therapeutics(RLAY.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 41.8% and a
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $15 to $28
On Jun 07, major Wall Street analysts update their ratings for $Relay Therapeutics(RLAY.US)$, with price targets ranging from $15 to $28.BofA Securities analyst Jason Gerberry maintains with a buy rat
Relay Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/07/2024 172.85% HC Wainwright & Co. $20 → $20 Reiterates Buy → Buy 05/10/2024 104.64% Barclays $15 → $1
Express News | Relay Therapeutics Inc : Leerink Partners Raises Target Price to $19 From $18
Comments
$Relay Therapeutics(RLAY.US$ Reuters· 1 min ago
Relay Therapeutics Announces Clinical Trial Collaboration With Pfizer to Evaluate Atirmociclib in Combination With Rly-2608
Relay Therapeutics Announces Clinical Trial Collaboration With Pfizer to Evaluate Atirmociclib in Combination With Rly-2608
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
Analysts' downgrade of Relay Therapeutics' revenue estimates and prediction of an accelerated decline in revenues compared to industry average growth rate suggest a bearish outlook. The unchanged price target implies business performance in line with expectations despite downward sales forecast adjustment.
$Microsoft(MSFT.US$ $C3.ai(AI.US$ $Alphabet-C(GOOG.US$ $Exscientia(EXAI.US$ $Relay Therapeutics(RLAY.US$
Oppenheimer strategist John Stoltzfus has outlined 10 predictions for the transformative impact of generative AI across various industries. The key focus of generative AI lies in its revolutionary potential to create entirely novel designs and products that may surpass human imagination.
1. Healthcare Augm...
Oppenheimer strategist John Stoltzfus has outlined 10 predictions for the transformative impact of generative AI across various industries. The key focus of generative AI lies in its revolutionary potential to create entirely novel designs and products that may surpass human imagination.
1. Healthcare Augm...
3
$Relay Therapeutics(RLAY.US$ Check this! Revenue 25.2M, up from 344K YoY! and EPS was -.54 versus estimated was -.83! I Like it. And im watching to see if the market likes it?![]()
Read more